Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease (NT-pro-MICI)

Centre Hospitalier Universitaire, Amiens

Status: Terminated

Conditions: NT-pro-BNP; Inflammatory Bowel Diseases

Treatments: Other: Evaluate the blood level of NTproBNP

Study type: Interventional

Funder types: Other

Identifiers

NCT03107390

PI2013_843_0015

Details and patient eligibility

About

NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology.

Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.

Enrollment: 159 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult subjects (age 18 years)
• MICI Group: Patients monitored for probable HC or MC
• Control group: Patients referred for consultation in gastroenterology with a clinical and endoscopic picture eading to the diagnosis of TF I
• Person who agreed to participate in the study
• Patient covered by social insurance

Exclusion criteria

• Causes of increased concentrations of natriuretic peptides: acute heart failure, acute or chronic pulmonary disease with right ventricular repercussion, valvulopathies, primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes, cirrhosis with ascites, cancers, chronic renal insufficiency.
• Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory syndrome
• Ongoing treatment that may affect the concentration of natriuretic peptides: ACE inhibitor, angiotensin II receptor antagonists, diuretics
• Patient deprived of liberty or protected major (under guardianship or curatorship)

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

159 participants in 2 patient groups

Patients with CD or RCH

Other group

Treatment:

Other: Evaluate the blood level of NTproBNP

The control population

Other group

Treatment:

Other: Evaluate the blood level of NTproBNP